Welcome to our dedicated page for UFP TECHNOLOGIES SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UFP Technologies Inc. filings document operating results and material events for its medical-device contract development and manufacturing business. Form 8-K reports furnish quarterly and annual earnings releases, non-GAAP financial measures, Regulation FD investor presentation materials, material definitive agreements with strategic medical customers, cybersecurity incident disclosures, and executive succession and compensation arrangements.
Proxy filings cover board elections, executive compensation, equity awards, pay-versus-performance disclosure, and shareholder voting matters. These records frame the company's governance, capital and incentive structure, customer-contract disclosures, and public reporting obligations as a Nasdaq-listed operating company.
UFP TECHNOLOGIES INC (UFPT) director Marc D. Kozin reported selling a total of 7,000 shares of common stock on 2026-08-25 in two open-market or private transactions. The reported per-share prices are weighted averages over price ranges, and post-transaction share holdings are not stated in this filing.
UFP Technologies Inc. (UFPT) disclosed a planned sale of 7,000 shares of common stock under Rule 144 for the account of director Marc D. Kozin, with shares held in the Marc D. Kozin Revocable Trust U/A 7/28/23 and to be sold through Fidelity Brokerage Services. The notice lists an aggregate market value of $2,140,950.00 for these shares. The shares derive from stock awards granted between 2019 and 2023 totaling 3,258 shares, with specified vesting dates from 2020 to 2024. Shares outstanding are shown as 7,713,300, a baseline figure, not the amount being sold.
UFP Technologies, Inc. (UFPT) furnished updated investor presentation materials describing its MedTech-focused contract development and manufacturing business and multi-year performance. The company positions itself as a partner for medical device and sterile packaging solutions, serving large OEMs, niche device makers, and start-ups across six countries with more than 5,000 team members.
The presentation highlights revenue of $603 million in 2025, up from $179 million in 2020, with a reported 3.4× revenue growth over that period. Adjusted operating margin is shown rising from 10.0% in 2020 to 17.1% in 2025, and the company reports 29.0% gross margin and 17.2% adjusted operating margin year-to-date through June 30, 2026. As of August 17, 2026, the presentation states a market capitalization of approximately $2.5 billion.
Management outlines 3–5 year financial targets of 12–18% annual revenue growth, 28–31% gross margins, and 17–20% adjusted operating margins, supported by an organic growth and customer-centric M&A strategy focused on higher-growth medical segments such as robotic assisted surgery, infection control, cardiovascular, and wound care.
UFP Technologies Inc (UFPT) director Symeria Hudson reported an open-market sale of the company’s common stock. The transaction involved 298 shares of Common Stock, $.01 par value, sold on 2026-08-18 at a price of $319.11 per share. After this sale, Hudson directly holds 927 shares of UFP Technologies common stock.
UFP Technologies director Symeria Hudson reported option-related trades in Common Stock. On August 13, 2026, Hudson exercised stock options covering 703 shares at an exercise price of $167.98 per share and 493 shares at $260.92 per share, acquiring the same number of common shares. On August 14, 2026, Hudson sold 1,926 common shares in open-market or private transactions at a weighted average price of $324.58 per share, with individual sale prices ranging from $324.36 to $324.945.
Director Cynthia L. Feldmann sold 1,000 shares of UFP Technologies (UFPT) Common Stock, $.01 Par Value on 2026-08-13 in a sale classified as an open market or private transaction at $324.26 per share. Following this transaction, she directly holds 4,476 shares of UFPT common stock.
UFP Technologies insider(s) filed an amended Form 144 covering potential future sales of common stock through Merrill Lynch. The notice lists shares acquired via stock option exercises in 2023 and 2024 and stock awards in 2024–2026, with proposed sales extending to August 14, 2026.
UFP Technologies is registering a planned sale of 2,349 shares of common stock through Merrill Lynch on or after August 14, 2026, listed on NASDAQ. The shares have an aggregate market value of $625,145.67, compared with 7,745,790 shares of common stock outstanding.
The sale relates to equity compensation and option activity, including shares from stock option exercises dated June 7, 2023 and June 5, 2024, and stock awards granted on May 31, 2024, June 2, 2025, and June 1, 2026.
UFPT reporting person filed a Form 144 to sell common stock. The filing lists a planned sale of 1,000 shares of UFPT common stock through Merrill Lynch, with an anticipated sale date of August 13, 2026 on NASDAQ. The seller previously received stock awards used for compensation in 2023, 2024, and 2025, and has already sold 1,200 shares of common stock in a transaction on June 12, 2026.
UFP Technologies Inc insider Joseph John Hassett, a director, filed an amended Form 4 to correct his reported holdings of Common Stock, $.01 Par Value. The amendment states that, due to an administrative error, the prior filing understated his beneficial ownership; the correct amount beneficially owned following the reported transaction was 2,602 shares.